Efficacy and safety of neoadjuvant combination immunotherapy in surgically resectable malignant solid tumors: a systematic review and meta-analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Petricevic B, Kabiljo J, Zirnbauer R, et al. Neoadjuvant immunotherapy in gastrointestinal cancers - the new standard of care? Semin Cancer Biol. 2022 Jun 4;86(Pt 2):834–850. doi: 10.1016/j.semcancer.2022.05.015
   PubMedGoogle Scholar
• Matzner P, Sandbank E, Neeman E, et al. Harnessing cancer immunotherapy during the unexploited immediate perioperative period. Nat Rev Clin Oncol. 2020 May;17(5):313–326.
   PubMed Web of Science ®Google Scholar
• Zaidi N, Jaffee EM. Immunotherapy transforms cancer treatment. J Clin Invest. 2019 Jan 2;129(1):46–47. doi: 10.1172/JCI126046
   PubMed Web of Science ®Google Scholar
• Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018 May 24;378(21):1976–1986. doi: 10.1056/NEJMoa1716078
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 Mar;25(3):477–486.
   PubMed Web of Science ®Google Scholar
• Long GV, Menzies AM, Scolyer RA. Neoadjuvant checkpoint immunotherapy and melanoma: the time is now. J Clin Oncol. 2023 Jun 10;41(17):3236–3248. doi: 10.1200/JCO.22.02575
   PubMed Web of Science ®Google Scholar
• Schoenfeld JD, Hanna GJ, Jo VY, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial. JAMA Oncol. 2020 Oct 1;6(10):1563–1570. doi: 10.1001/jamaoncol.2020.2955
   PubMed Web of Science ®Google Scholar
• Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003 Sep;73(9):712–716.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011 Oct 18;343(oct18 2):d5928. doi: 10.1136/bmj.d5928
   PubMedGoogle Scholar
• Yue D, Liu W, Chen C, et al. Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients [article]. Transl Lung Cancer Res. 2022;11(2):263–276. doi: 10.21037/tlcr-22-106
   PubMed Web of Science ®Google Scholar
• Amaria RN, Reddy SM, Tawbi HA, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma [clinical trial, phase II; journal article; randomized controlled trial; research support, Non‐U.S. Gov’t; research support, U.S. Gov’t, Non‐P.H.S.]. Nature Med. 2018;24(11):1649–1654.
   PubMed Web of Science ®Google Scholar
• Vos JL, Elbers JBW, Krijgsman O, et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma [article]. Nat Commun. 2021;12(1). doi: 10.1038/s41467-021-26472-9
   Web of Science ®Google Scholar
• Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial [clinical trial, phase II; journal article; randomized controlled trial; research support, N.I.H., extramural; research support, non‐U.S. Gov’t]. Nat Med. 2021;27(3):504–514. doi: 10.1038/s41591-020-01224-2
   PubMed Web of Science ®Google Scholar
• Kaseb AO, Hasanov E, Cao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial [Journal: Article in Press]. Lancet Gastroenterol Hepatol. 2022;7(3):208–218. doi: 10.1016/S2468-1253(21)00427-1
   PubMed Web of Science ®Google Scholar
• Einerhand SMH, van Dijk N, van Dorp J, et al. Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (stage III) urothelial cancer. Int J Cancer. 2022 May 23;151(11):2004–2011. doi: 10.1002/ijc.34125
   PubMed Web of Science ®Google Scholar
• Guercio BJ, Pietzak EJ, Brown S, et al. Neoadjuvant nivolumab (N) +/- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC). J Clin Oncol. 2022;40(6 SUPPL):498–498. doi: 10.1200/JCO.2022.40.6_suppl.498
   Web of Science ®Google Scholar
• Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022 Jun;28(6):1178–1188.
   PubMed Web of Science ®Google Scholar
• Reuss JE, Anagnostou V, Cottrell TR, et al. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer. 2020 Sep;8(2):e001282.
   PubMed Web of Science ®Google Scholar
• André T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA Phase II Study. J Clin Oncol. 2023;41(2) :255–265. doi: 10.1200/JCO.22.00686
   PubMed Web of Science ®Google Scholar
• Cocorocchio E, Gandini S, Nezi L, et al. Primary ipilimumab/nivolumab followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: update on outcome [Conference Abstract]. J Clin Oncol. 2022;40(16):9574–9574. doi: 10.1200/JCO.2022.40.16_suppl.9574
   Web of Science ®Google Scholar
• D’Alessio A, Pai M, Spalding D, et al. Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: The PRIME-HCC trial [Conference Abstract]. J Clin Oncol. 2022;40(16):4093–4093. doi: 10.1200/JCO.2022.40.16_suppl.4093
   Web of Science ®Google Scholar
• Ferrucci PF, Duso BA, Nezi L, et al. Abstract CT167: neoadjuvant ipilimumab/nivolumab in locally advanced or oligometastatic melanoma: an open label, single arm, multi-institutional clinical study with molecular and immunological biomarker’s analysis. Cancer Res. 2022;82(12):CT167–CT167. doi: 10.1158/1538-7445.AM2022-CT167
   Google Scholar
• Su Y, Lin Y, Hsiao C, et al. P-124 Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma [Conference Abstract]. Ann Oncol. 2021;32:S141. doi: 10.1016/j.annonc.2021.05.179
   Web of Science ®Google Scholar
• Verschoor YL, Van Den Berg J, Beets G, et al. Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study. J Clin Oncol. 2022;40(16):3511–3511. doi: 10.1200/JCO.2022.40.16_suppl.3511
   Web of Science ®Google Scholar
• Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019 Jul;20(7):948–960.
   PubMed Web of Science ®Google Scholar
• van Dijk N, Gil-Jimenez A, Silina K, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020 Dec;26(12):1839–1844.
   PubMed Web of Science ®Google Scholar
• Chalabi M, Verschoor YL, Van den BJ. Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study. Ann Oncol. 2022;33(S1389):S1389. doi: 10.1016/j.annonc.2022.08.016
   Google Scholar
• Ferrarotto R, Bell D, Rubin ML, et al. Impact of neoadjuvant durvalumab with or without tremelimumab on CD8(+) tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial results. Clin Cancer Res. 2020 Jul 1;26(13):3211–3219. doi: 10.1158/1078-0432.CCR-19-3977
   PubMed Web of Science ®Google Scholar
• Grande E, Guerrero F, Puente J, et al. DUTRENEO trial: arandomized phase II trial of DUrvalumab and tremelimumab versus chemotherapy as aNEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature [journal: conference abstract]. J Clin Oncol. 2020;38(15):TPS4588–TPS4588.
   Web of Science ®Google Scholar
• Gao J, Navai N, Alhalabi O, et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 Dec;26(12):1845–1851.
   PubMed Web of Science ®Google Scholar
• Kanikarla Marie P, Haymaker C, Parra ER, et al. Pilot clinical trial of perioperative durvalumab and tremelimumab in the treatment of resectable colorectal cancer liver metastases. Clin Cancer Res. 2021 Jun 1;27(11):3039–3049. doi: 10.1158/1078-0432.CCR-21-0163
   PubMed Web of Science ®Google Scholar
• Lee HS, Jang HJ, Ramineni M, et al. A phase II window of opportunity study of neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 blockade for patients with malignant pleural mesothelioma. Clin Cancer Res. 2023 Feb 1;29(3):548–559. doi: 10.1158/1078-0432.CCR-22-2566
   PubMed Web of Science ®Google Scholar
• Yin PGJ, Koshkin VS, Cole S, et al. PrE0807: a phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC) [journal: conference abstract]. J Clin Oncol. 2021;39(15 SUPPL):4518–4518. doi: 10.1200/JCO.2021.39.15_suppl.4518
   Web of Science ®Google Scholar
• Hanna GJ, O’Neill A, Shin KY, et al. Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck. Clin Cancer Res. 2022 Feb 1;28(3):468–478. doi: 10.1158/1078-0432.CCR-21-2635
   PubMed Web of Science ®Google Scholar
• Cascone T, Kar G, Spicer JD, et al. Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial. Cancer Discov. 2023 Nov 1;13(11):2394–2411. doi: 10.1158/2159-8290.CD-23-0436
   PubMedGoogle Scholar
• Park J, Park E, Joung JG, et al. A phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer (KGOG 3046/TRU-D) [conference abstract]. Cancer Res. 2022;82(12):CT010–CT010. doi: 10.1158/1538-7445.AM2022-CT010
   Google Scholar
• Loi S, Francis PA, Zdenkowski N, et al. Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): a single-arm phase 2 trial [conference abstract]. J Clin Oncol. 2022;40(16):602. doi: 10.1200/JCO.2022.40.16_suppl.602
   Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019 Oct 17;381(16):1535–1546. doi: 10.1056/NEJMoa1910836
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019 Nov 21;381(21):2020–2031. doi: 10.1056/NEJMoa1910231
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277–1290. doi: 10.1056/NEJMoa1712126
   PubMed Web of Science ®Google Scholar
• Liu J, Blake SJ, Yong MC, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016 Dec;6(12):1382–1399.
   PubMed Web of Science ®Google Scholar
• Cascone T, William WN Jr., Weissferdt A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 Mar;27(3):504–514.
   PubMed Web of Science ®Google Scholar
• Burton EM, Tawbi HA. Bispecific antibodies to PD-1 and CTLA4: doubling down on T cells to decouple efficacy from toxicity. Cancer Discov. 2021 May;11(5):1008–1010. doi: 10.1158/2159-8290.CD-21-0257
   PubMed Web of Science ®Google Scholar
• Kalaora S, Nagler A, Wargo JA, et al. Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer. 2022 Apr;22(4):195–207.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 Nov 27;515(7528):568–571. doi: 10.1038/nature13954
   PubMed Web of Science ®Google Scholar
• Mestrallet G, Brown M, Bozkus CC, et al. Immune escape and resistance to immunotherapy in mismatch repair deficient tumors. Front Immunol. 2023;14:1210164. doi: 10.3389/fimmu.2023.1210164
   PubMed Web of Science ®Google Scholar
• Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol. 2010 Mar;7(3):153–162. doi: 10.1038/nrclinonc.2009.237
   PubMed Web of Science ®Google Scholar
• Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020 Apr;26(4):566–576.
   PubMed Web of Science ®Google Scholar
• Roudko V, Bozkus CC, Orfanelli T, et al. Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors. Cell. 2020 Dec 10;183(6):1634–1649.e17. doi: 10.1016/j.cell.2020.11.004
   PubMed Web of Science ®Google Scholar
• Salmon H, Remark R, Gnjatic S, et al. Host tissue determinants of tumour immunity. Nat Rev Cancer. 2019 Apr;19(4):215–227.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020 Jan 31;367(6477). doi: 10.1126/science.aax0182
   PubMed Web of Science ®Google Scholar
• Lozano AX, Chaudhuri AA, Nene A, et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat Med. 2022 Feb;28(2):353–362. doi: 10.1038/s41591-021-01623-z
   PubMed Web of Science ®Google Scholar
• Raynes G, Stares M, Low S, et al. Immune-related adverse events, biomarkers of systemic inflammation, and survival outcomes in patients receiving pembrolizumab for non-small-cell lung cancer. Cancers (Basel). 2023 Nov 21;15(23):5502. doi: 10.3390/cancers15235502
   PubMed Web of Science ®Google Scholar
• Yu Y, Wang S, Su N, et al. Increased circulating levels of CRP and IL-6 and decreased frequencies of T and B lymphocyte subsets are associated with immune-related adverse events during combination therapy with PD-1 inhibitors for liver cancer. Front Oncol. 2022;12:906824. doi: 10.3389/fonc.2022.906824
   PubMed Web of Science ®Google Scholar
• Shibata Y, Kishida T, Kouro T, et al. Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma. Front Pharmacol. 2023;14:1269935. doi: 10.3389/fphar.2023.1269935
   PubMed Web of Science ®Google Scholar
• Duan J, Cui L, Zhao X, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol. 2020 Mar 1;6(3):375–384. doi: 10.1001/jamaoncol.2019.5367
   PubMed Web of Science ®Google Scholar
• Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015 Sep;125(9):3384–3391. doi: 10.1172/JCI80011
   PubMed Web of Science ®Google Scholar
• Xu C, Chen YP, Du XJ, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018 Nov 8;363:k4226. doi: 10.1136/bmj.k4226
   PubMedGoogle Scholar
• Ramakrishnan R, Gabrilovich DI. Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunol Immunother. 2013 Mar;62(3):405–410. doi: 10.1007/s00262-012-1390-6
   PubMed Web of Science ®Google Scholar